undamentalytics Newsletter
Sign in

Immucell Corp income statement

In fiscal 2025, Immucell Corp reported revenue of $27.6m, up 4.3% on the year before, operating income of $1.6m (a 6.0% margin) and net income of −$1.0m, or −$0.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue545568101010111415191917262831
Cost of revenue————————5678111114191618
Gross profit22333465557798481112
Research and development212112112444444432
Selling and marketing011111222222333344
General and administrative111111112222222234
Operating income−1−1−10−0−021−0−1−1−10−2−6−224
Interest expense————————————000100
Income before tax−0−1−100−021−0−2−1−1−0−2−6−2−11
Income tax−0−0−000−010−000−0000000
Net income−0−0−000−011−0−2−1−1−0−2−6−2−11
Diluted EPS−$0.07−$0.13−$0.14$0.03$0.04−$0.06$0.38$0.12−$0.03−$0.42−$0.19−$0.14−$0.01−$0.32−$0.75−$0.26−$0.12$0.09
Diluted shares (average)3m3m3m3m3m3m3m4m5m5m7m7m8m8m8m8m9m9m
EBITDA−0−0−010032101130−3146

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FAMI vs ICCCICCC vs WFCFICCC vs RYMICCC vs LOCL

More: Agricultural Products & Services stocks compared, Consumer Staples sector, rankings of US companies

Figures from Immucell Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immucell Corp.